The US National Institutes of Health (NIH) and the Food and Drug Administration (FDA) should work together to bring products to market (Nature 471, 135; 2011) . A telling example reveals how well this can work.
In the early 2000s, the National Institute of Child Health and Human Development conducted clinical trials of 17P, a drug that successfully reduced pre-term birth by more than 30% in women who had experienced it previously (P. J. Meis et al. N. Engl. J. Med. 348, 2379 -2385 2003) . The FDA granted the drug orphan status in 2003 to motivate the pharmaceutical company behind 17P to apply for FDA approval, which was granted this year after using the same NIH trial for the approval process.
In the interim, compounding pharmacies sold the drug at about US$400 per course of treatment. Some insurance companies chose not to pay for it because the drug was not FDA approved, which increased their later spend on complications from preterm births that could have been avoided.
With 17P approved and
EU innovation must benefit society
The narrow focus on innovation in preparation for the next European Framework programme is steering environmental and health research in the wrong direction (Nature 473, 421; 2011). Although these fields do not promise immediate economic growth, they are crucial drivers of innovation, focusing on complex socioecological systems, stimulating technological solutions and providing the basis for the sustainability of all innovations.
The European Union's (EU's) 2020 strategy brands the 'Innovation Union' as essential for "smart, sustainable and inclusive growth". This carries the risk that growth, competitiveness and innovation will be taken as ends per se, ahead of human well-being and sustainability. It is worryingly similar to the dominant approach before the economic crisis -one that led to unsustainable use of resources, crippling biodiversity loss and increased greenhouse-gas emissions.
Innovation is not an end, but a means to promote sustainability, human health and well-being. We must target European innovation discourse, policies and actions towards socially meaningful innovation. Researchers in academia all too often lack access to drug-discovery infrastructure, hindering translation of NIHfunded basic research into new medicines. Although the pharmaceutical industry may step in, it tends to ignore disease types that it considers too risky.
NCATS would allow NIHfunded researchers to create proof-of-concept compounds for neglected-disease targets and biomarkers for drug development, and even to launch early-stage clinical studies. Such 'de-risked' projects would offer in-licensing opportunities for drug firms. The non-profit research community should also benefit (A. J. Stevens et al. N. Engl. J. Med. 364, 535-541; 2011) .
Contrary to Miller's view, "government bureaucrats" will not decide which drugs to pursue. NIH programmes slated to move into the NCATS involve researchers at universities, hospitals and institutes, mostly using peer review to allocate funding. protected from competition for 7 years, the pharmaceutical company raised the drug's price to $30,000 and sent stern letters to pharmacies. In a later announcement of FDA drugenforcement priorities, 17P was low on the list because no safety issues had been reported regarding pharmacies.
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This breakthrough would not have occurred had the NIH not focused on solving the costly and complex issue of preterm birth, or without the FDA having granted orphan status and publicly announcing its enforcement priorities. James P. Reichmann American HomePatient, Tennessee, USA. jim.reichmann@ahom.com 
